AAM said the report highlights that 90% of the brand biologics scheduled to lose exclusivity in the next 10 years do not have ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.

Tocilizumab-anoh is the seventh biosimilar by Celltrion to receive FDA approval, enhancing their treatment portfolio. Avtozma, the third biosimilar to Actemra, has received FDA approval for ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

The US Food and Drug Administration (FDA) has approved Avtozma (tocilizumab-anoh) as a biosimilar of the original reference biologic tocilizumab (Actemra), according to a January 30 announcement ...

Dr. Reddy’s Laboratories will develop and commercialise Shanghai Henlius Biotech’s biosimilar candidate to Johnson & Johnson’s multiple myeloma drugs Darzalex and Darzalex Faspro.

I’ve been reviewing software for PCMag since 2008, and I still get a kick out of seeing what's new in video and photo editing software, and how operating systems change over time. I was ...

AbbVie (NYSE:ABBV) is ticking up; according to a new Samsung Bioepis report, Humira's U.S. market share stays above 70% even with increasing biosimilar competition. Humira still dominated 96% of ...

Donald and Melania Trump arrive at the White House ahead of the inauguration ceremony on Monday in Washington, D.C. (Andrew Harnik/Getty Images) Donald Trump was sworn in as the 47th president of ...

And it was so, so terrifying. Everett Collection Historical / Alamy Stock Photo 2.The two people depicted in Grant Wood's "American Gothic" actually exist. This is what they looked like ...

HYDERABAD -Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for a double-digit share in its core U.S. market for its new launches ...

The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi. The biosimilar of IL-6 inhibitor ...